2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172904
    Antidiabetic agent 15 98%
    Antidiabetic agent 15 (compound 1B15) is a AT1R and NEP dual inhibitor. Antidiabetic agent 15 reduces the oxidative stress and restores the mitochondrial membrane potential.
    Antidiabetic agent 15
  • HY-172924
    NLX-266 2170564-20-0 98%
    NLX-266 is an orally active ERK1/2-biased 5-HT1A receptor agonist. NLX-266 can be used in the study of Parkinson's disease.
    NLX-266
  • HY-172933
    Nav1.8 modulator 1 3004789-60-7 98%
    Nav1.8 modulator 1 (compound 1) is a potent Nav1.8 modulator. Nav1.8 modulator 1 has the potential for pain research.
    Nav1.8 modulator 1
  • HY-172941
    VEN-02XX 98%
    VEN-02XX is an orally active and brain-permeable NLRP3 inhibitor. VEN-02XX inhibits the release of IL-1β and IL-18 (IC50 0.3 and 0.28 μM, respectively). VEN-02XX restores memory and cognition, inhibits microgliosis, and reduces neuroinflammation and tau pathology in the 5XFAD/Rubicon KO mouse model. VEN-02XX may be used in the study of Alzheimer's disease (AD).
    VEN-02XX
  • HY-172942
    SP11 2629218-24-0 98%
    SP11 is a mitochondrial reactive oxygen species (ROS) inhibitor. SP11 activates Fis1 by binding to Cys41 (IC50: 9.4 µM) and increases the translocation of Drp1 to mitochondria. SP11 can be used in studies on the protection against oxidative stress damage.
    SP11
  • HY-172952
    LRRK2-IN-17 2101821-86-5 98%
    LRRK2-IN-17 (Compound 6) is an orally active LRRK2 inhibitor (IC50: 3.5 and 3.3 nM for WT and G2019S, respectively). LRRK2-IN-17 inhibits RET kinase (IC50: 59 nM). LRRK2-IN-17 can be used in cancer and Parkinson's disease (PD) research.
    LRRK2-IN-17
  • HY-172967
    SARM1-IN-5 2762081-30-9 98%
    SARM1-IN-5 (compound 1-23-a) is a SARM1 inhibitor. SARM1-IN-5 can be used in the study of axonal degeneration related diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
    SARM1-IN-5
  • HY-172972
    Mitochondrial-IN-1 2001090-87-3 98%
    Mitochondrial-IN (C458) is a potent mitochondrial complex I inhibitor. Mitochondrial-IN demonstrates high protection against Aβ toxicity, favorable pharmacokinetics, and minimal off-target effects.
    Mitochondrial-IN-1
  • HY-172973
    TAU-IN-4 2109305-45-3 98%
    TAU-IN-4 (compound I1.21) is a potent Tau aggregation inhibitor with a KD of 1.58 μM. TAU-IN-4 can be used in the study of Alzheimer’s disease.
    TAU-IN-4
  • HY-172974
    PTC-700 2476726-76-6 98%
    PTC-700 is a potent microtubule-associated protein tau (MAPT) splicing modulator. PTC-700 reduces 4R MAPT in both P301L and S305N neurons with EC50s of 1.3-1.8 nM, and 0.5-2.6 nM, respectively.
    PTC-700
  • HY-172977
    FGA139 98%
    FGA139 is a cysteine proteases inhibitor with IC50 values of 4.98/3.14 μM for cathepsin B/L. FGA139 reduces LPS-induced NO production in RAW264.7 cells and tumor necrosis factor (TNFα) levels in microglia, and has anti-oxidative stress and anti-inflammatory activities. FGA139 promotes the secretion of neuroprotective metabolites purine and linoleic acid by LPS-stimulated microglia. FGA139 can be used in neuroinflammatory diseases research.
    FGA139
  • HY-172978
    5-HT2A receptor agonist-8 2855122-44-8 98%
    5-HT2A receptor agonist-8 (compound 8) is a potent 5-HT2A receptor agonist with an EC50 of 0.6784nM. 5-HT2A receptor agonist-8 can be used in the study of depressive disorders and bipolar disorders.
    5-HT2A receptor agonist-8
  • HY-172979
    DH-1-106 98%
    DH-1-106 is a MOR partial agonist. DH-1-106 can be used in the study of analgesia.
    DH-1-106
  • HY-172980
    5-HT2A receptor agonist-9 3035280-33-9 98%
    5-HT2A receptor agonist-9 (Compound 9) is a β-arrestin-biased 5-HT2A receptor agonist. 5-HT2A receptor agonist-9 can be used in the research of neurological diseases such as antidepressant and psychedelic.
    5-HT2A receptor agonist-9
  • HY-172981
    CTW0404 2913202-87-4 98%
    CTW0404 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0404 is promising for research of neuropsychiatric disorders.
    CTW0404
  • HY-172982
    CTW0419 98%
    CTW0419 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0419 is promising for research of neuropsychiatric disorders.
    CTW0419
  • HY-172985
    CIT-ALD 211800-31-6
    CIT-ALD is an aldehyde intermediate in the metabolism of Citalopram (HY-121203). CIT-ALD is promising for research of neurological diseases.
    CIT-ALD
  • HY-172997
    GluN1/3A-IN-1 1147526-22-4 98%
    GluN1/3A-IN-1 (Compound GM-10) is a GluN1/GluN3A NMDA receptor inhibitor. GluN1/3A-IN-1 exhibits potent inhibitory activity against GluN1/GluN3A (IC50: 0.98 µM). GluN1/3A-IN-1 exerts its inhibitory effect by targeting the pre-M1 region and forming hydrogen bond interactions with key residues. GluN1/3A-IN-1 can be used to study GluN1/GluN3A-related neurological diseases.
    GluN1/3A-IN-1
  • HY-172998
    Nav1.8-IN-18 3003828-55-2 98%
    Nav1.8-IN-19 (Compound 70) is a Nav1.8 inhibitor.
    Nav1.8-IN-18
  • HY-172999
    Nav1.8-IN-19 3003829-05-5 98%
    Nav1.8-IN-19 (Compound 122) is a Nav1.8 inhibitor.
    Nav1.8-IN-19
Cat. No. Product Name / Synonyms Application Reactivity